Total amount raised
$914.8 Million
Latest funding date
9/1/2026
Location
Insilico Medicine has successfully raised significant funding over multiple rounds, leveraging its innovative AI-driven platform for drug discovery and development. The company's strategic approach has attracted a diverse group of investors, underscoring the potential and impact of its cutting-edge technologies.
What Is Insilico Medicine?
Insilico Medicine is a biotechnology company specializing in generative AI for drug discovery and development. The company operates multiple offices worldwide, including locations in Boston, New York, Montreal, Suzhou, Abu Dhabi, Shanghai, Taipei, and Hong Kong.
Insilico Medicine's mission is to extend healthy productive longevity by transforming drug discovery and development with generative AI. The company offers a suite of AI-driven products and has a robust therapeutic pipeline targeting various diseases.
How Much Funding Has Insilico Medicine Raised?
- Series A
- Amount Raised: $2.8M
- Date: February 2017
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's AI-driven drug discovery platform.
- Series A
- Amount Raised: $4M
- Date: July 2017
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand research and development capabilities.
- Series A
- Amount Raised: $6M
- Date: June 2018
- Lead Investors: WuXi AppTec
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop AI algorithms and drug discovery processes.
- Series B
- Amount Raised: $37M
- Date: September 2019
- Lead Investors: Qiming Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and enhance AI capabilities.
- Series C
- Amount Raised: $255M
- Date: June 2021
- Lead Investors: Warburg Pincus
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate drug discovery and expand the therapeutic pipeline.
- Corporate Round
- Amount Raised: Not publicly disclosed
- Date: January 2022
- Lead Investors: Fosun Pharma
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To form strategic partnerships and enhance market reach.
- Series D
- Amount Raised: $60M
- Date: June 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support late-stage clinical trials and regulatory approvals.
- Series D
- Amount Raised: $35M
- Date: August 2022
- Lead Investors: Prosperity7 Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the drug discovery pipeline and enhance AI platforms.
- Debt Financing
- Amount Raised: $100M
- Date: December 2024
- Lead Investors: HSBC Hong Kong
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To secure working capital and support ongoing projects.
- Series E
- Amount Raised: $110M
- Date: January 2025
- Lead Investors: Pudong Chuangtou, Value Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance AI platforms, upgrade laboratory infrastructure, and advance drug candidates.
- IPO
- Amount Raised: HKD 2,350.3 million (net proceeds to the company from the Global Offering, including the full exercise of the over-allotment option on January 16, 2026; HKD 2.277 billion raised at listing before the option)
- Date: December 2025
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund clinical development of its key clinical-stage drug candidates, early-stage drug discovery, new generative AI models, expansion of its automated lab and working capital.
- Convertible Bonds
- Amount Raised: USD 305,000,000 (aggregate principal of zero coupon convertible bonds due 2027; net proceeds approximately USD 302 million)
- Date: September 2026
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund clinical trials of self-developed drug candidates, expand the R&D team, develop frontier foundation models and supplement working capital.
Total Amount Raised: $914.8M. Current Valuation: Not publicly disclosed. Excludes the December 2025 IPO, stated in HKD (HKD 2,350.3 million net), and the undisclosed January 2022 Fosun Pharma corporate round.
Key Investors
- Pudong Venture Capital
- Details: Pudong Venture Capital is a Shanghai-based venture capital firm known for its investments in high-growth sectors.
- Investment Focus Areas: Biotechnology, AI, high-growth sectors
- Notable Investments: Not publicly disclosed
- Value Partners Group
- Details: Value Partners Group is a Hong Kong-based investment management firm with a diverse portfolio.
- Investment Focus Areas: Biotechnology, AI, diverse sectors
- Notable Investments: Not publicly disclosed
- HSBC Hong Kong
- Details: HSBC Hong Kong is a leading international bank with a strong presence in Asia.
- Investment Focus Areas: Banking, financial services, technology
- Notable Investments: Not publicly disclosed
- Prosperity7 Ventures
- Details: Prosperity7 Ventures is a global venture capital firm that invests in transformative technologies.
- Investment Focus Areas: Technology, healthcare, energy
- Notable Investments: Not publicly disclosed
- Warburg Pincus
- Details: Warburg Pincus is a global private equity firm with a focus on growth investing.
- Investment Focus Areas: Healthcare, technology, financial services
- Notable Investments: Not publicly disclosed
What's Next for Insilico Medicine?
Insilico Medicine stands at the cusp of significant growth, driven by its $110 million Series E, its December 2025 Hong Kong listing and $305 million in September 2026 convertible bonds. This capital infusion will enable the company to enhance its AI platforms, upgrade laboratory infrastructure, and advance its drug candidates, including a promising treatment for idiopathic pulmonary fibrosis. The biotechnology sector's increasing investment in AI-powered drug discovery presents a substantial opportunity for Insilico Medicine to lead the market.
Future fundraising opportunities appear promising, given the successful Series E round and the ongoing development of innovative drug candidates. However, the company must navigate challenges such as effectively utilizing the raised funds, advancing drug candidates through clinical trials, and facing competition from other AI-driven biotechnology firms. The strategic focus on AI and drug development positions Insilico Medicine well for potential future investments or acquisition offers from larger pharmaceutical companies.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Insilico Medicine and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
